Passage Bio Inc., a biotechnology company, has presented its latest corporate update, focusing on advancements in the treatment of neurodegenerative diseases. The presentation highlights the development of PBFT02, a gene therapy aimed at raising progranulin levels for conditions such as Frontotemporal Dementia (FTD) caused by GRN mutations. The company has established a suspension-based manufacturing process to support the late-stage development of this therapy. Passage Bio expects its cash reserves to sustain operations until the end of the first quarter of 2027. The upcoming milestones include reporting updated interim safety and biomarker data from Dose 2 in the second half of 2025 and seeking regulatory feedback on their manufacturing process and trial design in the first half of 2026. The presentation underscores the significant market opportunity for PBFT02 across various neurodegenerative disorders, including ALS and Alzheimer's Disease. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.